A global research synthesis highlights ongoing hurdles for T-cell receptor (TCR) therapies in ovarian cancer, including tumor heterogeneity, on-target off-tumor toxicity, and insufficient trafficking into the immunosuppressive ovarian tumor microenvironment. Investigators report variable antigen expression, limited persistence of engineered T cells, and checkpoint-mediated suppression as recurrent obstacles in early trials. Authors outline strategies under investigation: affinity-tuned TCRs, regional delivery, and combination with microenvironment-modulating agents. The review stresses the need for refined antigen selection and robust translational biomarkers to guide patient selection and combination regimens for TCR programs in solid tumors.